Triptorelin

CHEMBL1201334 Phase 4 Đã phê duyệt Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1311.4 g/mol
LogP
-0.3
Phase
4

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that, upon continuous administration, causes pituitary desensitization and downregulation of GnRH receptors, leading to suppression of luteinizing hormone, follicle-stimulating hormone, and consequently sex hormone production. It is used for prostate cancer (androgen deprivation therapy), breast cancer, endometriosis, and precocious puberty. Its mechanism exploits the paradox that continuous GnRH receptor stimulation leads to receptor desensitization and hormonal castration.

Khối lượng phân tử

1311,4000 g/mol

LogP

-0,30

TPSA

490,00 Ų

Lipinski RO5

Không đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

InChI

InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1

Molecular Formula

C64H82N18O13

HBD / HBA

17 / 15

Liên kết có thể quay

33

Nguyên tử nặng

95

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that, upon continuous administration, causes pituitary desensitization and downregulation of GnRH receptors, leading to suppression of luteinizing hormone, follicle-stimulating hormone, and consequently sex hormone production. It is used for prostate cancer (androgen deprivation therapy), breast cancer, endometriosis, and precocious puberty. Its mechanism exploits the paradox that continuous GnRH receptor stimulation leads to receptor desensitization and hormonal castration.

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Yes, Triptorelin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201334. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25074470. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.